Avalo Therapeutics’ (AVTX) Outperform Rating Reaffirmed at Wedbush

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “outperform” rating reiterated by Wedbush in a report issued on Thursday,RTT News reports. They currently have a $18.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 134.99% from the stock’s current price. Wedbush also issued estimates for Avalo Therapeutics’ Q1 2025 earnings at $0.63 EPS.

Other research analysts have also recently issued research reports about the company. BTIG Research initiated coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company. Piper Sandler initiated coverage on Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Stock Performance

AVTX opened at $7.66 on Thursday. The business has a 50 day moving average of $7.45 and a 200-day moving average of $9.11. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Institutional Trading of Avalo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in shares of Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $114,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $145,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $168,000. Finally, Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $446,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.